Home › Myasthenia Gravis › NCT07596901
Study of Aritinercept in Patients With Generalized Myasthenia Gravis
A Double-Blind, Randomized, Placebo-Controlled Study to Investigate the Safety and Efficacy of Aritinercept, a Dual BAFF/APRIL Inhibitor, in Patients With Generalized Myasthenia Gravis
Who can join
Ages 18 to 85 · All sexes
Full eligibility criteria
Key Inclusion Criteria: * Adult patients (18-85 years old) * Myasthenia Gravis Foundation of America (MGFA) Class II-IV gMG * Additional inclusion criteria are defined in the protocol Key Exclusion Criteria: * Current or medical history of malignancy within the last 5 years * Pregnant, breastfeeding or intending to become pregnant during the Study * Additional exclusion criteria are defined in the protocol
About the study
This clinical study will enroll patients with generalized myasthenia gravis (gMG). The goal of this clinical study is to assess the safety, tolerability, effectiveness, pharmacokinetics (how the body processes the drug) and pharmacodynamics (how the drug affects the body) of aritinercept.
What is being tested
- Aritinercept (drug)
- Placebo (other)
Sponsor: Aurinia Pharmaceuticals Inc. · Participants: 81 · Started: Apr 22, 2026
Contact the study team
- Aurinia Clinical Trials Information · Phone: 833-606-5975
Official record on ClinicalTrials.gov — NCT07596901
Locations in the U.S.
Conditions
From ClinicalTrials.gov, data retrieved Sep 29, 2026. Each study sets its own eligibility; the study team decides who can join.